BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC₅₀s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively. IC50 & Target: IC50: 7 nM (LIMK1), 8 nM (LIMK2)^[1] In Vitro: BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2^ΔEx2 mouse Schwann cells (MSCs) with an IC₅₀ of ~2 µM. BMS-5 (LIMKi 3) reduces Nf2^ΔEx2 MSC viability in a dose-dependent manner with an IC₅₀ of 3.9 µM, but does not significantly reduce the viability of control Nf2^flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 µM BMS-5, Nf2^ΔEx2 MSC viability is 40% compared to 83% for controls^[2]. In Vivo: BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01)^[3].